INTRAVESICAL RESINIFERATOXIN FOR THE TREATMENT OF INTERSTITIAL CYSTITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

2005200 citationsJournal Article

Authors

Christopher K. Payne · Cardiovascular Institute of the South

PHILIP G. MOSBAUGH · Cardiovascular Institute of the South

John B. Forrest · Cardiovascular Institute of the South

Robert J. Evans · Cardiovascular Institute of the South

Kristene Whitmore · Cardiovascular Institute of the South

Joseph P. Antoci · Cardiovascular Institute of the South

Ramon Perez-Marrero

Abstract

In the largest prospective, randomized clinical trial reported to date with intravesical vanilloid therapy, single administration of RTX at doses of 0.01 microM to 0.10 microM was not effective in patients with interstitial cystitis.

Topics & Keywords

Urinary Bladder and Prostate Research Plant Toxicity and Pharmacological Properties Silymarin and Mushroom Poisoning

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Urology

Volume 173, Issue 5, pp. 1590-1594

DOI: 10.1097/01.ju.0000154631.92150.ef

Field-Weighted Citation Impact: 19.39